Details of the Drug
General Information of Drug (ID: DMF1X5P)
| Drug Name |
Proflavine
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
PRL; Proflavin; Proflavina; Proflavinum; Profura; Progarmed; Isoflav base; Proflavine [INN]; Proflavine hemisulfate; Proflavina [INN-Spanish]; Proflavine Hemi-Sulfate; Proflavinum [INN-Latin]; AE-562/12222295; Acridine-3,6-diamine; 2,8-Diaminoacridine; 2,8-Diaminoacridine (European); 2,8-Diaminoacridinium; 3,6-ACRIDINEDIAMINE; 3,6-Acridinediamine hydrochloride; 3,6-Diamino-acridinium; 3,6-Diaminoacridine; 3,6-Diaminoacridine sulfate; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Therapeutic Class |
Antiinfective Agents
|
||||||||||||||||||
| Affected Organisms |
Enteric bacteria and other eubacteria
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 209.25 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.8 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||


